Wealth Advisors of Iowa LLC decreased its stake in shares of Bristol-Myers Squibb (NYSE: BMY – Get Rating) by 31.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,546 shares of the biopharmaceutical company stock after selling 1,627 shares during the period. Wealth Advisors of Iowa LLC’s holdings in Bristol-Myers Squibb were worth $ 221,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp boosted its stake in shares of Bristol-Myers Squibb by 2.2% during the 4th quarter. State Street Corp now owns 94,645,972 shares of the biopharmaceutical company stock valued at $ 5,901,176,000 after purchasing an additional 2,020,678 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Bristol-Myers Squibb by 3.3% during the 3rd quarter. Wellington Management Group LLP now owns 45,407,364 shares of the biopharmaceutical company stock valued at $ 2,686,754,000 after purchasing an additional 1,444,304 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Bristol-Myers Squibb by 2.5% during the 4th quarter. Geode Capital Management LLC now owns 37,863,099 shares of the biopharmaceutical company stock valued at $ 2,354,737,000 after purchasing an additional 922,811 shares in the last quarter. Primecap Management Co. CA boosted its stake in shares of Bristol-Myers Squibb by 16.9% during the 4th quarter. Primecap Management Co. CA now owns 22,114,455 shares of the biopharmaceutical company stock valued at $ 1,378,836,000 after purchasing an additional 3,195,680 shares in the last quarter. Finally, Nordea Investment Management AB boosted its stake in shares of Bristol-Myers Squibb by 20.8% during the 4th quarter. Nordea Investment Management AB now owns 18,130,455 shares of the biopharmaceutical company stock valued at $ 1,136,598,000 after purchasing an additional 3,124,811 shares in the last quarter. 73.07% of the stock is currently owned by hedge funds and other institutional investors.
BMY opened at $ 73.02 on Thursday. The firm has a market cap of $ 155.46 billion, a P / E ratio of 25.89, a PEG ratio of 1.60 and a beta of 0.49. Bristol-Myers Squibb has a 1-year low of $ 53.22 and a 1-year high of $ 78.61. The company has a 50 day simple moving average of $ 76.17 and a two-hundred day simple moving average of $ 69.14. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.32 and a quick ratio of 1.23.
Bristol-Myers Squibb (NYSE: BMY – Get Rating) last issued its earnings results on Friday, April 29th. The biopharmaceutical company reported $ 1.96 earnings per share for the quarter, topping analysts’ consensus estimates of $ 1.92 by $ 0.04. Bristol-Myers Squibb had a net margin of 13.31% and a return on equity of 48.37%. The firm had revenue of $ 11.65 billion during the quarter, compared to analyst estimates of $ 11.34 billion. During the same quarter in the prior year, the business earned $ 1.74 earnings per share. Bristol-Myers Squibb’s revenue for the quarter was up 5.2% on a year-over-year basis. Equities analysts anticipate that Bristol-Myers Squibb will post 7.55 earnings per share for the current year.
In other news, EVP Sandra Leung sold 65,000 shares of the company stock in a transaction dated Monday, June 6th. The shares were sold at an average price of $ 74.89, for a total value of $ 4,867,850.00. Following the transaction, the executive vice president now directly owns 308,627 shares in the company, valued at $ 23,113,076.03. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Giovanni Caforio sold 25,000 shares of the stock in a transaction dated Monday, March 21st. The stock was sold at an average price of $ 71.52, for a total transaction of $ 1,788,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 120,000 shares of company stock valued at $ 8,877,050. 0.09% of the stock is owned by company insiders.
Several equities research analysts recently commented on BMY shares. Morgan Stanley dropped their price objective on shares of Bristol-Myers Squibb from $ 66.00 to $ 64.00 and set an “underweight” rating on the stock in a research note on Wednesday, April 6th. Barclays lifted their target price on shares of Bristol-Myers Squibb from $ 66.00 to $ 68.00 in a report on Monday, May 2nd. Bank of America lifted their target price on shares of Bristol-Myers Squibb from $ 78.00 to $ 80.00 and gave the stock a “buy” rating in a report on Monday, June 6th. Citigroup reaffirmed a “buy” rating and issued a $ 90.00 target price on shares of Bristol-Myers Squibb in a report on Friday, June 3rd. Finally, Wells Fargo & Company lifted their target price on shares of Bristol-Myers Squibb from $ 65.00 to $ 70.00 and gave the stock an “equal weight” rating in a report on Tuesday, May 17th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $ 74.27.
About Bristol-Myers Squibb: (Get Rating)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke / systemic embolism in NVAF, and for the treatment of DVT / PE; Opdivo for anti-cancer indications; Pomalyst / Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.
Recommended Stories:
Receive News & Ratings for Bristol-Myers Squibb Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bristol-Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.
.